Carla Moran1, Maura Agostini1, W Edward Visser1, Erik Schoenmakers1, Nadia Schoenmakers1, Amaka C Offiah2, Ken Poole3, Odelia Rajanayagam1, Greta Lyons1, David Halsall4, Mark Gurnell1, Dionisios Chrysis5, Alexandra Efthymiadou5, Charles Buchanan6, Simon Aylwin7, Krishna K Chatterjee8. 1. University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. 2. Academic Unit of Child Health, University of Sheffield, Sheffield, UK. 3. Department of Rheumatology, Addenbrooke's Hospital, Cambridge, UK. 4. Department of Clinical Biochemistry, Addenbrooke's Hospital, Cambridge, UK. 5. Department of Paediatrics, Division of Endocrinology, Medical School University of Patras, Patras, Greece. 6. Department of Child Health, King's College Hospital, London, UK. 7. Department of Endocrinology, King's College Hospital, London, UK. 8. University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. Electronic address: kkc1@medschl.cam.ac.uk.
Abstract
BACKGROUND: The thyroid hormone receptor α gene (THRA) transcript is alternatively spliced to generate either thyroid hormone receptor (TR)α1 or a non-hormone-binding variant protein, TRα2, the function of which is unknown. Here, we describe the first patients identified with a mutation in THRA that affects both TRα1 and TRα2, and compare them with patients who have resistance to thyroid hormone owing to a mutation affecting only TRα1, to delineate the relative roles of TRα1 and TRα2. METHODS: We did clinical, biochemical, and genetic analyses of an index case and her two sons. We assessed physical and radiological features, thyroid function, physiological and biochemical markers of thyroid hormone action, and THRA sequence. FINDINGS: The patients presented in childhood with growth failure, developmental delay, and constipation, which improved after treatment with thyroxine, despite normal concentrations of circulating thyroid hormones. They had similar clinical (macrocephaly, broad faces, skin tags, motor dyspraxia, slow speech), biochemical (subnormal ratio of free thyroxine:free tri-iodothyronine [T3], low concentration of total reverse T3, high concentration of creatine kinase, mild anaemia), and radiological (thickened calvarium) features to patients with TRα1-mediated resistance to thyroid hormone, although our patients had a heterozygous mis-sense mutation (Ala263Val) in both TRα1 and TRα2 proteins. The Ala263Val mutant TRα1 inhibited the transcriptional function of normal receptor in a dominant-negative fashion. By contrast, function of Ala263Val mutant TRα2 matched its normal counterpart. In vitro, high concentrations of T3 restored transcriptional activity of Ala263Val mutant TRα1, and reversed the dominant-negative inhibition of its normal counterpart. High concentrations of T3 restored expression of thyroid hormone-responsive target genes in patient-derived blood cells. INTERPRETATION: TRα1 seems to be the principal functional product of the THRA gene. Thyroxine treatment alleviates hormone resistance in patients with mutations affecting this gene, possibly ameliorating the phenotype. These findings will help the diagnosis and treatment of other patients with resistance to thyroid hormone resulting from mutations in THRA. FUNDING: Wellcome Trust, NIHR Cambridge Biomedical Research Centre, Marie Curie Actions, Foundation for Development of Internal Medicine in Europe.
BACKGROUND: The thyroid hormone receptor α gene (THRA) transcript is alternatively spliced to generate either thyroid hormone receptor (TR)α1 or a non-hormone-binding variant protein, TRα2, the function of which is unknown. Here, we describe the first patients identified with a mutation in THRA that affects both TRα1 and TRα2, and compare them with patients who have resistance to thyroid hormone owing to a mutation affecting only TRα1, to delineate the relative roles of TRα1 and TRα2. METHODS: We did clinical, biochemical, and genetic analyses of an index case and her two sons. We assessed physical and radiological features, thyroid function, physiological and biochemical markers of thyroid hormone action, and THRA sequence. FINDINGS: The patients presented in childhood with growth failure, developmental delay, and constipation, which improved after treatment with thyroxine, despite normal concentrations of circulating thyroid hormones. They had similar clinical (macrocephaly, broad faces, skin tags, motor dyspraxia, slow speech), biochemical (subnormal ratio of free thyroxine:free tri-iodothyronine [T3], low concentration of total reverse T3, high concentration of creatine kinase, mild anaemia), and radiological (thickened calvarium) features to patients with TRα1-mediated resistance to thyroid hormone, although our patients had a heterozygous mis-sense mutation (Ala263Val) in both TRα1 and TRα2 proteins. The Ala263Val mutant TRα1 inhibited the transcriptional function of normal receptor in a dominant-negative fashion. By contrast, function of Ala263Val mutant TRα2 matched its normal counterpart. In vitro, high concentrations of T3 restored transcriptional activity of Ala263Val mutant TRα1, and reversed the dominant-negative inhibition of its normal counterpart. High concentrations of T3 restored expression of thyroid hormone-responsive target genes in patient-derived blood cells. INTERPRETATION: TRα1 seems to be the principal functional product of the THRA gene. Thyroxine treatment alleviates hormone resistance in patients with mutations affecting this gene, possibly ameliorating the phenotype. These findings will help the diagnosis and treatment of other patients with resistance to thyroid hormone resulting from mutations in THRA. FUNDING: Wellcome Trust, NIHR Cambridge Biomedical Research Centre, Marie Curie Actions, Foundation for Development of Internal Medicine in Europe.
Authors: Max P Huang; Kathryn A Rodgers; Rosemary O'Mara; Meetal Mehta; Hilal S Abuzahra; Andrew D Tannenbaum; Kelly Persons; Michael F Holick; Joshua D Safer Journal: Thyroid Date: 2011-09-21 Impact factor: 6.568
Authors: César Venero; Ana Guadaño-Ferraz; Ana Isabel Herrero; Kristina Nordström; Jimena Manzano; Gabriella Moreale de Escobar; Juan Bernal; Björn Vennström Journal: Genes Dev Date: 2005-08-30 Impact factor: 11.361
Authors: C Saltó; J M Kindblom; C Johansson; Z Wang; H Gullberg; K Nordström; A Mansén; C Ohlsson; P Thorén; D Forrest; B Vennström Journal: Mol Endocrinol Date: 2001-12
Authors: Alies A van Mullem; Dionisios Chrysis; Alexandra Eythimiadou; Elizabeth Chroni; Agathocles Tsatsoulis; Yolanda B de Rijke; W Edward Visser; Theo J Visser; Robin P Peeters Journal: J Clin Endocrinol Metab Date: 2013-04-30 Impact factor: 5.958
Authors: Ryan K C Yuen; Bhooma Thiruvahindrapuram; Daniele Merico; Susan Walker; Kristiina Tammimies; Ny Hoang; Christina Chrysler; Thomas Nalpathamkalam; Giovanna Pellecchia; Yi Liu; Matthew J Gazzellone; Lia D'Abate; Eric Deneault; Jennifer L Howe; Richard S C Liu; Ann Thompson; Mehdi Zarrei; Mohammed Uddin; Christian R Marshall; Robert H Ring; Lonnie Zwaigenbaum; Peter N Ray; Rosanna Weksberg; Melissa T Carter; Bridget A Fernandez; Wendy Roberts; Peter Szatmari; Stephen W Scherer Journal: Nat Med Date: 2015-01-26 Impact factor: 53.440
Authors: Xiaofei Gao; Hsiang-Ying Lee; Wenbo Li; Randall Jeffrey Platt; M Inmaculada Barrasa; Qi Ma; Russell R Elmes; Michael G Rosenfeld; Harvey F Lodish Journal: Proc Natl Acad Sci U S A Date: 2017-09-01 Impact factor: 11.205
Authors: Cho Rong Han; Erik Holmsen; Blake Carrington; Kevin Bishop; Yuelin Jack Zhu; Matthew Starost; Paul Meltzer; Raman Sood; Paul Liu; Sheue-Yann Cheng Journal: Thyroid Date: 2020-02 Impact factor: 6.568